Pfizer's unsuccessful takeover of AstraZeneca Case Study

Pfizers unsuccessful takeover of AstraZeneca - Case Study usageIn this regard, it is necessary to have a brief knowledge about AstraZeneca. The come with is a join Kingdom (UK) based pharmaceutical alliance headquartered in London. AstraZeneca is also recognised among top companies in the orbicular pharmaceutical industry. Like Pfizer, this company also have significant experience in acquisition and mergers as it has acquired and collaborated with a number of companies in recent years.The case in this paper focuses on the failed merger amid Pfizer and AstraZeneca which took place in May, 2014. It was gathered from the Guardian (2014a) that the chairman of Pfizer initially approached chairman of AstraZeneca regarding merger in November 2013 turn the detailed discussion took place in January, 2014. The exploratory meeting between some(prenominal) the companies took place in New York on January 5, 2014. It was gathered that Pfizer offered a settlement payment of 58 billion or 46 .61 per administer in its preliminary proposal to AstraZeneca. The offer also included establishment of a new safekeeping company listed and headquartered in the US. However, AstraZenecas board turned down the offer concluding that Pfizer has heavily undervalued the company and its prospects. The company also questioned transaction structure and offered inversion structure of Pfizer and ultimately the proposal ended by the mid of January 2014 (International Business Times, 2014 The Telegraph, 2014 The Guardian, 2014a 2014b).On 26 April 2014, Pfizer contacted chairman of AstraZeneca for a new discussion regarding collaboration of both the companies but AstraZeneca declined this offer. Consequently, Pfizer publicised its interest in merger with AstraZeneca on 28 April 2014. The US pharmaceutical giant star revealed that they are planning to offer AstraZeneca cash and share at an attractive premium. They further added that they would move company domicile